

***HER-2/neu* gene amplification in gastric adenocarcinoma and its relationship with clinical and pathological findings**

Ramin Azarhoosh¹, Rokhsare Ebneghasem², Sima Besharat³

¹Clinical Research Development Unit (CRDU), 5 azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran; ²Infectious Diseases Research Center, ³Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran

Contributions: (I) Conception and design: R Ebneghasem, R Azarhoosh; (II) Administrative support: R Azarhoosh, S Besharat; (III) Provision of study material or patients: R Ebneghasem, R Azarhoosh; (IV) Collection and assembly of data: R Ebneghasem; (V) Data analysis and interpretation: R Ebneghasem, S Besharat; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Rokhsare Ebneghasem, Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Email: rokhsareebneghasem@yahoo.com.

Background: Amplification of the *HER-2/neu* oncogene influences the progression of gastric cancer, its prognosis, and therapy. A precise examination of *HER-2/neu*-amplified tumor tissue is essential for managing disease and prescribing the appropriate treatment. This study aimed to investigate the status of *HER-2/neu* gene in the gastric cancer samples and its relationship with clinical and pathological information.

Methods: In this study on 80 paraffin-embedded tissue samples from patients with gastric adenocarcinoma [2006–2011], DNA was extracted to quantify the gene expression levels of *HER-2* using a polymerase chain reaction (PCR) method. Data were statistically analyzed by chi-square test using SPSS16.0 software.

Results: PCR results indicated that *HER-2/neu* gene amplifications occurred in 58 of the 80 samples (72.5%). *HER-2/neu* gene expression was not significantly related to age and sex, but the larger tumor size and the more advanced stage were significantly associated with *HER-2/neu* overexpression.

Conclusions: The data show the *HER-2/neu* gene is more amplified in stage 4 of gastric cancer with a larger size of mass. Older age and male sex also appear to be more associated with *HER-2/neu* gene expression.

Keywords: Gastric adenocarcinoma; polymerase chain reaction (PCR); *HER-2/neu* amplification

Submitted Jul 29, 2017. Accepted for publication Sep 20, 2017.

doi: 10.21037/jgo.2017.10.11

View this article at: <http://dx.doi.org/10.21037/jgo.2017.10.11>

Introduction

Cancer, a disease with unchecked abnormal cells proliferation affecting adjacent tissues; is the second leading cause of death in human beings after heart diseases. Cancer cells can spread through the blood or lymph to other parts of the body (1).

Upper gastrointestinal cancers, including gastric cancer, are among the most common cancers (2–6). Reports from different parts of the world revealed very different results, but a higher incidence of gastric cancer in males compared to females is common (7).

A report from Iran [2012] showed that 11.4% of all cancer cases were attributable to gastric cancer, one which

was considered as the second most prevalent cancer in the country. It was also presumed to be the most deadly cancer in Iran (GLOBOCAN, 2012), accounting for 15.5% of all mortalities caused by cancer (8).

Since gastric cancer is mainly diagnosed in advanced stages, identifying patients at risk using sensitive and specific diagnostic methods seems very useful. Despite the decline in gastric cancer rates in recent decades, it is still the major cause of mortality due to cancer. It has been shown that 39% of deaths due to cancer are related to gastric cancer (3).

Investigations showed that more than 750,000 people die annually from gastric cancer, and men are at risk for gastric cancer 2 times more than women. Gastric adenocarcinoma

is the most common type of gastric cancer originating from the glandular tissues of the stomach. Other types of gastric cancer are lymphoma and sarcoma which originates in lymphoid and connective tissues, respectively (9,10).

Oncogenes come from certain genes called proto-oncogenes. Proto-oncogene products induce proliferation, but oncogenes are activated in elevated levels than normal. Proto-oncogene involved in cancer development can be divided into several groups, such as growth factors and cell-surface receptors like erythroblastosis oncogene B (erbB) or *HER-2/neu*. One of the most important abnormalities leading to cancer is oncogene over-expression.

Gene amplification means an increase in the number of copies in a limited area of the chromosome that leads to more than two copies of genes in that area. As a result, it causes an increase of critical genes involved in cancer onset and its progression (11). Of growth factors a cell needs, an epidermal growth factor (EGF) is the most famous one which has receptors on the surface of target cells called EGF receptor (EGFR) and *HER-2* receptor (12).

HER-2/neu is the most important amplified oncogene in gastric cancer. Amplified *HER-2/neu* gene and its over-expression have been reported in patients with gastric cancer. *HER-2/neu* proto-oncogene, located on chromosome 17 (q12-21), is a transmembrane glycoprotein consisting of 125 amino acids and weighing 185Kd. *HER-2/neu* codes an intrinsic tyrosine kinase activity, which is one of a four-member family of the EGF receptor. Normally, *HER-2/neu* is expressed in numbers of cells and tissues, and plays important roles in intracellular signaling, growth, differentiation, survival, and cell adhesion pathways (13).

Compared to the microscopic techniques, molecular techniques such as polymerase chain reaction (PCR) are faster, more accurate, cheaper, and easier (14). PCR is a semi-quantitative method to measure the amplification of *HER-2/neu* gene. Number of genes like TATA-box binding protein and INF γ (interferon gamma) is clear in cell structures, making them potent genes used as controls. In this method, the target gene with unknown copy number and the control gene with the known copy number (two copies per cell) are simultaneously amplified in a tube. Increased level of target gene is determined by the ratio of target gene and control band's intensities in tumor samples in comparison with normal tissues, giving the relative copy number of the target gene (15).

As the northern and northwestern regions of Iran are high-risk areas for gastric cancer, compared to other

geographical areas, this study was designed to measure the *HER-2/neu* gene expression in tissue samples of patients with gastric adenocarcinoma through PCR (after selecting INF γ gene as a control gene with two constant copies in cells).

Methods

In this case control study, 80 paraffin-embedded tissue samples of the gastric adenocarcinoma cases were selected from our academic hospital, pathology department [2006–2011]. This study was approved by Golestan University of Medical Sciences (Ethics Committee IR.GOUMS. REC.1395.290) and the informed consent was taken from all the patients.

Samples were taken from those cases that underwent gastrectomy (totally or partially). Demographic data such as age and gender were recorded and a pathologist reported the tumor size and staging of tumor.

Staging of tumor has been done for all cases based on data obtained during the main surgery recoding in the medical records and the pathological findings.

Ethical consideration

The study protocol has been approved in the local ethical committee of Golestan University of Medical Sciences. The informed consent has been taken during the main surgery for all becoming procedures.

Deparaffinization

A 6-micron section of paraffin blocks had been prepared and stored in sterile micro tubes. A deparaffinization method was used to extract DNA. For deparaffinization, we firstly added 1 mL xylol (Merck, Germany) to each vial and put them into thermo mixer devices (Eppendorf, Germany) in a temperature of 59 °C for 10 minutes; then, we centrifuged them for 10 min in 12,000 rpm. This step was taken again on the pellet of vial bottom. Finally, after supplying water with alcohol, the pellet without paraffin was used to extract DNA. For so doing, TBE (200 μ L) and lysis buffer (400 μ L) were added to the deparaffinized pellet and it was kept for one hour in a thermocycler. Then, we added chloroform (60 μ L) to it and kept it for 3–5 minutes at room temperature. After 2 minutes of centrifugation, the supernatant was moved into another 1.5 mL microtome. Certain ratios of precipitation buffers and distilled water were added to it and it was




Figure 1 *HER-2* gene Amplification by PCR in paraffin-embedded tumor tissue samples of adenocarcinoma cancer patients. Columns 1, 3, 4, 6, and 8 are wells containing amplified *HER-2* genes and columns 2, 5, and 7 include tumor samples without amplified *HER-2* genes. Column 9 shows a 50 bp DNA ladder (Fermentas Germany). PCR, polymerase chain reaction.

placed at room temperature. After centrifugation, 100 μ L of NaCl was added to the pellet, and after a one-minute vortex, 300 μ L of ice ethanol was added to it and it froze at -20°C for one day.

PCR procedure

Primer sequences used for *HER-2* and *INF γ* (internal control) were:

F: 5'CATCAACTGCACCCACTCCT3' R: 5'GCAGCAGTCTCCGCATCGTG3' and F: 5'ATG AAATAT ACA AGT TAT ATCTTG GCTTT3' R: 5'GAT GCT CTT CGA CCT CGA AAC AGC AT3', respectively. Both primer parameters, including primer dimers, and a lack of connection failure of the 3' ends were determined by the Oligo 5 software. Primer pair products were over 100 and 150 bp for *HER-2/neu* and *INF γ* genes, respectively. PCR reactions were performed in a final volume of 25 μ L. PCR mixture was comprised of 2.5 μ L PCR buffer, 1.5 μ L MgCl_2 , 10 pmol of each primer, 1 μ L dNTPs, 0.5 μ L SmarTaq DNA Pol, and 5 μ L genomic DNA. Water was added to bring the mixture to the final volume of 25 μ L. Thermo cycles (Eppendorf, Germany) and thermal conditions for PCR initiated denaturation at 94°C for 10 minutes followed by 35 cycles including denaturation at 94°C for 1 minute, annealing at 62°C for 1 minute, extension at 70°C for 1 minute, and the final expansion step was done at 72°C for 10 minutes.

The PCR products were cast in the wells of 1.5% agarose gel. A 100-bp DNA Ladder (SM0313Fermentase) was poured in one of the wells. Since the good answer was obtained by PCR reaction, the same program was repeated with more samples, and the rest of the PCR samples run on 1.5% gel electrophoresis. The proportion of Band intensity or density of *HER-2/neu* to *INF γ* band's for each sample was determined using the Image J software. The app was downloaded from <http://rsbweb.nih.gov/ij>. Considering the relative copy number of the *HER-2/neu* gene in each sample and gene amplification, a 2-fold or more increase in *HER-2/neu* band intensity over *INF γ* band intensity was observed.

Results

Tissue samples were taken from 80 gastric adenocarcinoma cases with mean (standard deviation) age of 67.92 (12.03) years. Mean tumor size was 2.96 (0.66) cm and 50 of them were males (62.5%). Eighteen patients (22.5%) were stage 3 and 62 patients (77.5%) were stage 4.

Amplification of *HER-2/neu* (Figure 1) showed overexpression of this gene in 58 samples (72.5%).

As shown in Table 1, *HER-2/neu* overexpression was detected in 82.3% of stage 4 tumors versus 38.9% of cases with stage 3 tumors. This difference was statistically significant (P value =0.000).

Tumor sizes analysis showed that the expression of *HER-2/neu* tumors and significantly larger than 3 cm in size can be seen (P value =0.000).

HER-2/neu overexpression was found in 40 males (80%) and 18 females (60%) (P value =0.052). There was no significant difference in *HER-2/neu* gene overexpression between cases younger and older than 60 years old (P value =0.098).

Discussion

Any increase in parts of genome containing oncogenes, such as *HER-2/neu*, would play a key role in the onset and development of tumors (16,17). Overexpression of *HER-2/neu* gene has been reported in 92–95% of gastric cancer cases (18,19). Routine methods used for assessing gene expression are immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Despite their simplicity, IHC method is easy, simple, fast, and low-cost that detects a 2-fold increase in gene amplification even in small amounts of tumor tissue. Techniques have low accuracy and often yield false-positive results in patients

Table 1 Measuring the HER-2/neu expression in different stages of gastric adenocarcinoma

Stage of tumor	HER-2/neu expression, N (%)		Total, N (%)	P value
	Negative	Positive		
Stage 3	11 (61.1)	7 (38.9)	18 [100]	0.000
Stage 4	11 (17.7)	51 (82.3)	62 [100]	
Total, N (%)	22 [100]	58 [100]	80 [100]	

with IHC+ (20).

PCR In this study, *HER-2/neu* gene amplification in gastric adenocarcinoma samples using PCR method showed an increased level of *HER-2/neu* gene in 58 out of 80 samples.

Overexpression of *HER-2/neu* gene amplifications has been reported in more than 30% of breast, as well as colorectal cancer cases in other studies (19,21,22).

Furthermore, there is a direct relationship between *HER-2/neu* and gastric carcinoma stages which a study conducted by García *et al.* verified it (23). In a study by Al-Moundhri *et al.*, the frequency of the her2 marker was obtained in 54% of patients with gastric cancer (16). Park *et al.* found that *HER-2/neu* is an important marker in the prognosis of the disease. They studied 82 patients with the gastric adenocarcinoma that 29 samples (15.9%) of them showed *HER-2/neu* marker and a lower 5-year survival rate was reported in *HER-2/neu* positive cases (24).

Overexpression of *HER-2/neu* gene may be the result of high gene transcription of *HER-2/neu*. Increased transcription of the gene may be directed by activating mutations in genes controlling *HER-2/neu* expression or increased expression of transcription factors involved in *HER-2/neu* transcription (25,26).

Conclusions

Present results showed that *HER-2/neu* gene expression is significantly more seen in stage 4 of gastric cancer with a larger size of mass. Older age and male sex were also associated with a higher level of *HER-2/neu* gene expression, although not significant.

Acknowledgements

This paper was extracted from MSc thesis dedicated to achieve MSc degree in Genetic.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: This study was approved by Golestan University of Medical Sciences (Ethics Committee IR.GOUMS.REC.1395.290) and the informed consent was taken from all the patients.

References

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61:69-90.
2. DavoodAbadi A, Sharifi H, Erfan N, et al. An epidemiologic and clinical survey on gastric cancer patients referred to Shahid Beheshti Hospital of Kashan (1994-2001). *Razi Journal of Medical Sciences* 2003;10:211-20.
3. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. *Arch Iran Med* 2009;12:576-83.
4. Babaei M, Pourfarzi F, Yazdanbod A, et al. Gastric cancer in Ardabil, Iran--a review and update on cancer registry data. *Asian Pac J Cancer Prev* 2010;11:595-9.
5. Krejs GJ. Gastric cancer: epidemiology and risk factors. *Dig Dis* 2010;28:600-3.
6. Androli T, Carpenter C, Griggs R, et al. Diseases of the liver and biliary system. *Cecil's Essentials of Medicine* 7th ed. USA: WB Saunders Company, 2007;23.
7. Haidari M, Nikbakht MR, Pasdar Y, et al. Trend analysis of gastric cancer incidence in Iran and its six geographical areas during 2000-2005. *Asian Pac J Cancer Prev* 2012;13:3335-41.
8. Kavousi A, Bashiri Y, Mehrabi Y, et al. Identifying high-risk clusters of gastric cancer incidence in Iran, 2004 - 2009. *Asian Pac J Cancer Prev* 2014;15:10335-7.
9. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. *CA Cancer J*

- Clin 2014;64:252-71.
10. Jarrell BE. Schwartz's principles of surgery. LWW; 2005.
 11. O'Hagan RC, Chang S, Maser RS, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. *Cancer Cell* 2002;2:149-55.
 12. Orangy E, Hojati Z, Ghaedi K, et al. Comparison of the HER2/neu gene amplification assesment by differential PCR and immunohistochemistry in breast cancer patients in Isfahan. *Journal of Shahrekord University of Medical Sciences*. 2012;13:71-82.
 13. Tapia C, Savić S, Wagner U, et al. HER2 gene status in primary breast cancers and matched distant metastases. *Breast Cancer Res* 2007;9:R31.
 14. Barberis M, Pellegrini C, Cannone M, et al. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. *Am J Clin Pathol* 2008;129:563-70.
 15. Zadrozny M, Smolarz B, Romanowicz-Makowska H, et al. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer. *Pol J Pathol* 2002;53:189-93.
 16. Al-Moundhri MS, Nirmala V, Al-Hadabi I, et al. The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. *J Surg Oncol* 2005;91:243-52.
 17. Kuwahara Y, Tanabe C, Ikeuchi T, et al. Alternative mechanisms of gene amplification in human cancers. *Genes Chromosomes Cancer* 2004;41:125-32.
 18. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. *Oncogene* 1996;13:63-72.
 19. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989;244:707-12.
 20. Jacobs TW, Gown AM, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. *Am J Clin Pathol* 2000;113:251-8.
 21. Venter DJ, Tuzi NL, Kumar S, et al. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. *Lancet* 1987;2:69-72.
 22. Ghaffarzadegan K, Sharifi N, Vosooghnia H, et al. HER2/neu expression in colon adenocarcinoma and its correlation with clinicopathologic variables. *IJBMS* 2006;1:64-9.
 23. García I, Vizoso F, Martín A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. *Ann Surg Oncol* 2003;10:234-41.
 24. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. *Dig Dis Sci* 2006;51:1371-9.
 25. Hurst HC. Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. *Breast Cancer Res* 2001;3:395-8.
 26. Scott GK, Chang CH, Erny KM, et al. Ets regulation of the erbB2 promoter. *Oncogene* 2000;19:6490-502.

Cite this article as: Azarhoosh R, Ebneghasem R, Besharat S. *HER-2/neu* gene amplification in gastric adenocarcinoma and its relationship with clinical and pathological findings. *J Gastrointest Oncol* 2017. doi: 10.21037/jgo.2017.10.11